US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

29.25

+0.0000

Post-market: 29.15-0.1000-0.34%18:58 EDT

Volume:417.06K

Turnover:12.18M

Market Cap:- -

PE:- -

High:29.33

Open:29.08

Low:29.04

Close:29.25

Loading ...

Overview Company News Filings

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Coming back to CES after a decade-long break was a trip

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Wave Life Sciences announces submission of CTA for WVE-007

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Intelligent Product Solutions Partners with The Digital Medicine Society (DiMe) Initiative to Advance Digitally-Enabled Hospital-at-Home Care

Business Ownership Reporting Requirement Placed on Hold by Federal Judge -- Barrons.com

Charles River Introduces Global Biotech Incubator Program

Are managed futures ETFs nearing a Europe comeback?

Millions of Americans Have Failed to Comply With New Tax Ownership Rules -- Barrons.com

DIC to Unveil Omnidirectional Multicopter HAGAMOSphere™, Named as CES Innovation Awards® 2025 Honoree, at CES 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":29.25,"timestamp":1743105600000,"preClose":29.25,"halted":0,"volume":417062,"hourTrading":{"tag":"盘后","latestPrice":29.15,"preClose":29.25,"latestTime":"18:58 EDT","volume":525,"amount":15313.29,"timestamp":1743116320642},"delay":0,"floatShares":32225001,"shares":0,"eps":0,"marketStatus":"Closed","change":0,"latestTime":"03-27 16:00:00 EDT","open":29.08,"high":29.33,"low":29.04,"amount":12181313.341279998,"amplitude":0.009915,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743148800000},"marketStatusCode":5,"adr":0,"exchange":"AMEX","adjPreClose":29.25,"sharesOutstanding":32225001,"nav":29.22,"aum":941541052.63,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.15,"preClose":29.25,"latestTime":"18:58 EDT","volume":525,"amount":15313.29,"timestamp":1743116320642},"volumeRatio":0.762809,"impliedVol":0.0916,"impliedVolPercentile":0.3548},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":32225001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.762809,"shares":0,"dividePrice":1.1919,"high":29.33,"amplitude":0.009915,"preClose":29.25,"low":29.04,"week52Low":24.824,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":29.25,"eps":0,"divideRate":0.040749,"volume":417062,"delay":0,"ttmEps":0,"open":29.08,"prevYearClose":27.89,"prevWeekClose":29.67,"prevMonthClose":28.73,"prevQuarterClose":27.89,"fiveDayClose":29.92,"twentyDayClose":28.91,"sixtyDayClose":27.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503997818","title":"Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2503997818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503997818?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:55","pubTimestamp":1737035700,"startTime":"0","endTime":"0","summary":"MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Appro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/16/3010810/0/en/Metagenomi-Highlights-Progress-Across-Therapeutic-Portfolio-and-Outlines-Anticipated-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4109","ASH","LU2463526074.USD","BK4097","LU2065732104.USD","PRGS","MGX","CTA","AGT"],"gpt_icon":0},{"id":"2503677942","title":"Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677942?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":"- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/15/3010436/0/en/Solid-Biosciences-Outlines-Key-Priorities-for-Advancing-Diversified-Neuromuscular-and-Cardiac-Development-Pipeline-and-Establishing-Leadership-in-Precision-Genetic-Medicines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDN","BK4144","LU2089284900.SGD","LU1162221912.USD","BK4516","BK4127","LU2023251221.USD","BK4588","LU2357305700.SGD","MDCO","LU1363072403.SGD","LU1732800096.USD","BK4130","LU0106261372.USD","BK4023","LU0795875169.SGD","BK4535","LU1732799900.SGD","LU1074936037.SGD","LU2089283258.USD","LU1720051108.HKD","IE00BKVL7J92.USD","LU2347655156.SGD","FA","BK4534","BK4121","BK4539","CTA","LU0158827781.USD","GENE","GLP","BK4585","LU0225283273.USD","LU0971096721.USD","LU0106831901.USD","LU2111349929.HKD","IE00BZ1G4Q59.USD","BK4590","LU0006306889.USD","BK4139","BK4504","LU0795875086.SGD","LU1989772840.SGD","LU0267386448.USD","SLDB","LU0314104364.USD","LU0912757837.SGD","LU0098860793.USD","LU1989772923.USD","LU2271345857.HKD"],"gpt_icon":0},{"id":"2503147307","title":"Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2503147307","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503147307?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:00","pubTimestamp":1736776800,"startTime":"0","endTime":"0","summary":"Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities. -- Achieved in vivo preclinical proof of concept of editing hematopoietic. stem cells in non-human primates as a key step toward developing a novel. in vivo treatment for sickle cell disease and beta thalassemia. -- Achieved in vivo editing of liver cells in non-human primates and in vivo. delivery to two additional cell types in humanized mice. -- Anticipated 2025 milestones include: declare two in vivo development. candidates, one in HSCs and one in liver; present further in vivo HSC. data; present in vivo data in one liver indication; establish one. additional target cell type/tissue; and continue to derive revenue. New In Vivo Proof of Concept Data in Non-human Primates and Humanized Mice Highlighting the Potential of Editas' Gene Upregulation Strategy Across Tissues","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","BK4139","BK4556","BK4585","BK4588","PACI.U","LU1861558580.USD","CTA","EDIT","LU1861559042.SGD"],"gpt_icon":0},{"id":"2502809389","title":"Coming back to CES after a decade-long break was a trip","url":"https://stock-news.laohu8.com/highlight/detail?id=2502809389","media":"The Verge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502809389?lang=en_us&edition=fundamental","pubTime":"2025-01-11 13:00","pubTimestamp":1736571600,"startTime":"0","endTime":"0","summary":"Twelve years ago, I could have told you exactly what happened at my first CES and what happened at my third. Each was a chapter with a beginning, middle, and end; the lines between them drawn clearly.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theverge.com/2025/1/11/24340285/ces-2025-robots-ai-sphere","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theverge_highlight","symbols":["GB00BDT5M118.USD","BK4551","LU1814569148.SGD","SG9999015952.SGD","BK4503","BK4022","IE0002270589.USD","IE00BZ199S13.USD","SG9999014880.SGD","SG9999014914.USD","SG9999015978.USD","LU0642271901.SGD","LU2264538146.SGD","SG9999018865.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0719512351.SGD","SG9999014906.USD","SGXZ31699556.SGD","BK4230","BK4585","SG9999018857.SGD","LU1983260115.SGD","LU1316542783.SGD","BK4588","LU0127658192.USD","LU2087625088.SGD","UBER","LU1988902786.USD","BK4505","IE00B7SZLL34.SGD","LU0006306889.USD","LU0082616367.USD","BK4550","BK4535","LU1064131342.USD","LU0106261372.USD","LVCC","SG9999015945.SGD","BK4536","CTA","SG9999014898.SGD","LU0353189763.USD","LU0353189680.USD","SG9999017495.SGD","SG9999015986.USD"],"gpt_icon":1},{"id":"2502614022","title":"Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2502614022","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502614022?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:00","pubTimestamp":1736456400,"startTime":"0","endTime":"0","summary":"Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007342/0/en/Mural-Oncology-Highlights-Pipeline-Progress-and-Anticipated-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROC","CTA","BK4007","BK4097","LU2065732104.USD","PRGS","OS","MURA"],"gpt_icon":0},{"id":"2495509646","title":"Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509646","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509646?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:15","pubTimestamp":1735593300,"startTime":"0","endTime":"0","summary":"- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner. \"Giroctocogene fitelparvovec has demonstrated the potential to be a life changing gene therapy treatment for hemophilia A patients, and following positive results from the Phase 3 AFFINE trial, we believe it is well positioned for regulatory submissions and potential commercialization,\" said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. \"While we were surprised and extremely disappointed by Pfizer’s decision to end our collaboration so close to the anticipated BLA and MAA submissions, especially given the compelling pivotal clinical trial data, we appreciate their collaboration in leading a robust and successful clinical development program and for advancing the asset to this important stage. We are committed to exploring the optimal path forward for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-regain-full-rights-211500999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999001176.USD","LU0122379950.USD","LU0321505868.SGD","LU0321505439.SGD","ABR","LENZ","LU0225284248.USD","LU1066053197.SGD","BK4533","IE000M9KFDE8.USD","SG9999001176.SGD","CTA","LU0985481810.HKD","IE00B19Z3581.USD","LU1066051498.USD","LU1883839398.USD","SGMO","PFE","LU1894683348.USD","BK4592","BK4139","IE00BLSP4239.USD","LU0456855351.SGD","BK4581","BK4599","IE00BLSP4452.SGD","LU0058720904.USD","BK4534","BK4588","IE0002270589.USD","SG9999002232.USD","BK4585","LU1057294990.SGD","SG9999013999.USD","LU1894683264.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU0234572021.USD","SG9999002224.SGD","BK4007","LU0306806265.USD","LU0306807586.USD","MAA","SG9999003800.SGD","LU0868494617.USD","SG9999011175.SGD","IE00BBT3K403.USD","BK4568","BK4110","BK4550"],"gpt_icon":1},{"id":"2495588049","title":"Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2495588049","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495588049?lang=en_us&edition=fundamental","pubTime":"2024-12-29 19:25","pubTimestamp":1735471558,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now.In this article, we are going to take a look at where Prime Medicine, Inc. stands against the other gene therapy stocks.As per IMARC, healthcare infrastructure in the US adapted to accommodate gene therapies. As per IQVIA’s tally, 114 gene therapy trials were initiated in the year 2023. Out of this, a large majority  were sponsored by the healthcare industry. As per Kella Kapnisi, Head of Cell and Gene Therapy at Team Consulting , as of now, there are38 cell and gene therapies approved by the FDA. Notably, many of these have reached commercialization through mostly manual laboratory manufacturing processes.As per IMARC, the collaborations between biotech companies, pharmaceutical firms, and university research institutes can pool the funds needed to address challenges related to creating and promoting gene treatments.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prime-medicine-inc-prme-gene-112558617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","PRME","CTA","MNQmain","PSQ","QLD","TQQQ","BK4139","USAW.SI","USJW.SI","SQQQ","QID","TSYW.SI",".IXIC","NVIW.SI"],"gpt_icon":1},{"id":"2493750195","title":"Wave Life Sciences announces submission of CTA for WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750195","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750195?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:40","pubTimestamp":1734961219,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the submission of its first clinical trial application, CTA, for WVE-007 in obesity. WVE-007 is an investigation...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-announces-submission-of-cta-for-wve-007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-announces-submission-of-cta-for-wve-007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WVE","CTA","BK4007"],"gpt_icon":0},{"id":"2492900080","title":"Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900080","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900080?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:01","pubTimestamp":1734523260,"startTime":"0","endTime":"0","summary":"- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024. \"We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong,\" said Dr. Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences. \"PBGENE-HBV has been designed to target a viral site that is prevalent across all HBV genotypes, including in Asia, and we believe that this will enable us to evaluate and provide access to as many patients as possible. In addition to Hong Kong, our clinical trial site in Moldova continues to execute as planned, and we look forward to sharing clinical data as it matures throughout 2025.\". Through its precision cutting, compact design, and simple structure, PBGENE-HBV is engineered to target the HBV viral genome and drive functional","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vrgaD_Pt49bwoCl_NBdEqw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vrgaD_Pt49bwoCl_NBdEqw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-receives-approval-hong-120100591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","DTIL","BK4139"],"gpt_icon":0},{"id":"2492962857","title":"3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492962857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492962857?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:59","pubTimestamp":1734443940,"startTime":"0","endTime":"0","summary":"Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing deals or acquisitions.Gene therapy enables the modification of a patient’s gene to treat or cure the underlying disease. The treatment involves either replacing a disease-causing gene with a healthy copy of the gene or disabling a disease-causing gene that is not functioning properly. A new or modified gene can also be introduced into the patient’s body to help treat a disease.The therapy takes a different approach from traditional drug therapies as it can treat the underlying cause and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-biotech-stocks-promising-gene-135900489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","SRPT","IE00B2B36J28.USD","LU1861559042.SGD","BK4585","IE00BJT1NW94.SGD","LU1861558580.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","VYGR","BK4139","CRSP","CTA","BK4556"],"gpt_icon":1},{"id":"2492095704","title":"Intelligent Product Solutions Partners with The Digital Medicine Society (DiMe) Initiative to Advance Digitally-Enabled Hospital-at-Home Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2492095704","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492095704?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:52","pubTimestamp":1734443520,"startTime":"0","endTime":"0","summary":"HAUPPAUGE, N.Y., Dec.  17, 2024  (GLOBE NEWSWIRE) -- Intelligent Product Solutions (IPS), an award-winning product design firm, today announced its partnership in the Advancing a Sustainable Hospital-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998297/0/en/Intelligent-Product-Solutions-Partners-with-The-Digital-Medicine-Society-DiMe-Initiative-to-Advance-Digitally-Enabled-Hospital-at-Home-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4195","CTA","HBCP","IPS","BK4202","FORD"],"gpt_icon":0},{"id":"2489255966","title":"Business Ownership Reporting Requirement Placed on Hold by Federal Judge -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2489255966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489255966?lang=en_us&edition=fundamental","pubTime":"2024-12-07 01:04","pubTimestamp":1733504640,"startTime":"0","endTime":"0","summary":"A federal judge has placed on hold a new requirement for more than 32 million businesses to report ownership information by Jan. 1 or face fines of up to $10,000.The businesses, including private corporations and pass-through entities, would have been required to file ownership information under the Corporate Responsibility Act of 2021  by year end, but only 25% were in compliance as of late November.Calling the requirement quasi-Orwellian and possibly unconstitutional, U.S. District Judge Amos L. Mazzant in Texas issued an injunction on Tuesday after six plaintiffs filed a suit claiming that the CTA's requirements are unconstitutional.The rule was an effort to build an ownership database to better equip U.S. Treasury to investigate financial crimes, which can be difficult to trace with tiered, complex entities and multiple owners.Companies that already file ownership information with an arm of the federal government, such as the Securities and Exchange Commission, were exempt.Lack of ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US2Y.BOND","US10Y.BOND","US12M.BOND","US5Y.BOND","US30Y.BOND","US7Y.BOND","CTA","US6M.BOND","US3Y.BOND"],"gpt_icon":0},{"id":"2489592459","title":"Charles River Introduces Global Biotech Incubator Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2489592459","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489592459?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:00","pubTimestamp":1733403600,"startTime":"0","endTime":"0","summary":"Program offers biotechnology developers access to extensive scientific expertise and a wide ecosystem of discovery, development and manufacturing capabilities. WILMINGTON, Mass., December 05, 2024----Charles River Laboratories International, Inc.  today announced the launch of the Charles River Incubator Program , specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.Building on the success of the Company’s established global Cell and Gene Therapy  Accelerator Program , the CIP focuses on nurturing innovative start-up and early-stage biotechnology companies. The objective of the CIP is to form a strong foundation for commercial viability as its participants gain momentum with the goal of imparting cost-effective, consultative regulatory and quality expertise, personnel training initiatives, and enabling access to laboratory space and equipment. Developers are invited to apply to be part of ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/soeFVJ8qIYJku70ZjXue0g--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a432d474cf8ee8b265d89d9e8938930f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/soeFVJ8qIYJku70ZjXue0g--~B/aD0zMjY7dz0xMjQ1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a432d474cf8ee8b265d89d9e8938930f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-introduces-global-biotech-130000386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4530","BK4139","BK4121","CTA","LU0390134368.USD","BK4585","CDMO","BK4588","CRL"],"gpt_icon":0},{"id":"2489541431","title":"Are managed futures ETFs nearing a Europe comeback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489541431","media":"ETF stream","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489541431?lang=en_us&edition=fundamental","pubTime":"2024-12-05 18:45","pubTimestamp":1733395500,"startTime":"0","endTime":"0","summary":"Managed futures ETFs have tried – and failed – to gain traction in Europe before, but the market might now be ready for another shot.In a managed futures strategy, a Commodity Trading Advisor (CTA) us","market":"us","thumbnail":"//images.ctfassets.net/lr0atmu04u9z/7imy04VoG9hwr1VQwRDaOY/0798f187a63e7a9e7c8aa7532b4655dd/shutterstock_1050436808.jpg","type":0,"news_type":0,"thumbnails":["//images.ctfassets.net/lr0atmu04u9z/7imy04VoG9hwr1VQwRDaOY/0798f187a63e7a9e7c8aa7532b4655dd/shutterstock_1050436808.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.etfstream.com/articles/are-managed-futures-etfs-nearing-a-europe-comeback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"etfstream_highlight","symbols":["BK4550","BK4588","BK4585","FDN","CTA"],"gpt_icon":0},{"id":"2488659142","title":"Millions of Americans Have Failed to Comply With New Tax Ownership Rules -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2488659142","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488659142?lang=en_us&edition=fundamental","pubTime":"2024-12-01 17:00","pubTimestamp":1733043600,"startTime":"0","endTime":"0","summary":"Whether you are an owner of a large private business with cross-border operations or a simple LLC holding a family cottage, it's likely that you are obligated to comply with new federal ownership disclosure rules by year-end -- but have failed to do so.Three-quarters of the 32 million private companies and pass-through entities that are required to file ownership information to the U.S. Department of Treasury's Financial Crimes Enforcement Network  starting this year still haven't done so, risking up to a $10,000 penalty or jail time for noncompliance.The new rules, passed under the Corporate Transparency Act  in 2021, apply to people who have substantial control or at least a 25% stake in a business or pass-through entity that isn't registered with a federal government agency such as the Securities and Exchange Commission.This generally includes LLCs and private corporations such as S corporations and businesses that were created by filing documents with a state government, and foreig","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2485772484","title":"DIC to Unveil Omnidirectional Multicopter HAGAMOSphere™, Named as CES Innovation Awards® 2025 Honoree, at CES 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2485772484","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485772484?lang=en_us&edition=fundamental","pubTime":"2024-11-22 10:00","pubTimestamp":1732240800,"startTime":"0","endTime":"0","summary":"DIC's omnidirectional architecture multirotor, HAGAMOSphere is the drone that can move forward, backward, left, and right without tilting the aircraft because eight propellers are mounted diagonally on a cubic frame. . DIC is a global fine chemical manufacturer with a diverse portfolio of products, including printing inks, pigments, and synthetic resins. Its management vision is \"We improve the human condition by safely delivering color and comfort for sustainable prosperity －Color & Comfort－,\" which seeks to provide color and comfort to society while working to solve social issues and provide new value to society.Under the concept of \"Direct to Society,\" DIC aims to propose new values to society beyond the framework of conventional chemical manufacturers and creating diverse businesses across industries in an ecosystem. At CES 2025, DIC will introduce \"HAGAMOSphere,\" its concept model, to capture various social needs and utilize it for future business creation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7S4XL_W6nn2ATC4avOEOCw--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26faefc43a683a20a74e640fb4ddfa69","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7S4XL_W6nn2ATC4avOEOCw--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26faefc43a683a20a74e640fb4ddfa69"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dic-unveil-omnidirectional-multicopter-hagamosphere-020000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DICCF","CTA","BK4109"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":63}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"},{"date":"2024-03-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-26","defaultRemindTime":1711373400000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","recordDate":"2024-03-28","payableDate":"2024-03-26","currency":"USD","dateTimestamp":1711339200000,"payDate":"2024-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}